Intramyocardial injection of DNA encoding vascular endothelial growth factor in a myocardial infarction model.

Abstract:

:In a previous study, we observed that one injection of 500 microg of DNA for the plasmid encoding for vascular endothelial growth factor (ph VEGF(165)) into one site in a rat myocardial infarction model resulted in neovascularization confined to angiomatous structures that did not contribute to regional myocardial blood flow. The purpose of the present study was to determine whether a lower dose (125 microg DNA), which is the same as that being used in some clinical trials, injected into four separate sites could enhance collateral flow and vascularity to the ischemic bed without inducing angiomas. Rats received injections of 125 microg DNA of the plasmid encoding phVEGF(165) or control DNA at four separate sites within the anterior free wall of the left ventricle (LV) supplied by the left coronary artery. The left coronary artery was ligated and hearts analyzed at 4 weeks. In vitro studies confirmed that the phVEGF(165) used was capable of producing VEGF polypeptide in mammalian cells. The infarct size (percentage of endocardial circumference that infarcted) was similar in controls (42+/-6%) and treated hearts (39+/-7%); the LV cavity area did not differ between groups. The number of vascular structures per high-power field within the infarct scar was 10.50+/-0.68 in controls and 10.00+/-0.85 in phVEGF(165)-treated rats. Relative regional myocardial blood flow determined by radioactive microspheres and expressed as a ratio of radioactive counts within the scar divided by radioactive counts in the noninfarcted ventricular septum was similar in control (0.74+/-0.25) and treated hearts (0.88+/-0.30) (p=not significant). No angiomatous structures were observed. Injections of 125 microg of DNA of phVEGF(165) into myocardium to become ischemic had no effect on infarct size or LV cavity size. Unlike higher doses of 500 microg of DNA, it did not cause gross angiomatous structures; however, it failed to improve neovascularization or regional myocardial blood flow in this rodent model of acute myocardial infarction.

journal_name

J Thromb Thrombolysis

authors

Kloner RA,Dow J,Chung G,Kedes LH

doi

10.1023/a:1026507627097

subject

Has Abstract

pub_date

2000-12-01 00:00:00

pages

285-9

issue

3

eissn

0929-5305

issn

1573-742X

journal_volume

10

pub_type

杂志文章
  • Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation.

    abstract::Whitmania pigra Whitman (W. pigra) has been widely employed in decoction for the treatment of blood stasis syndrome for many years in China. The aim of the present study was to explore the anti-venous thrombosis (VT) mechanism of the aqueous extract of W. pigra (AEW) in rats. Rats were orally administered with AEW. A ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02337-8

    authors: Li P,Lin B,Tang P,Ye Y,Wu Z,Gui S,Zhan Y,Yang W,Lin B

    更新日期:2020-11-17 00:00:00

  • Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

    abstract::Since the reports by Weismann and Tobin in 1958 and Roberts et al. in 1964 called attention to paradoxical thrombosis in patients treated with heparin, the thrombotic aspect of the heparin-induced thrombocytopenia syndrome (HIT) has been emphasized. Yet to this day, the mechanism of thrombosis associated with HIT (HIT...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1027372901367

    authors: Walenga JM,Jeske WP,Messmore HL

    更新日期:2000-11-01 00:00:00

  • Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.

    abstract:BACKGROUND:Oxidative stress play an important role triggering platelet/endothelial activation. AGI-1067 is a novel, phenolic antioxidant, and vascular protectant which dose-dependently inhibits PEA biomarkers in vitro. Whether treatment with AGI-1067 alters platelets in vivo is not known. We serially assessed release o...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-008-0233-y

    authors: Serebruany V,Malinin A,Qiu FH,Xu XC,Kunsch C,Scott R,ALPS Study Group.

    更新日期:2009-05-01 00:00:00

  • Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.

    abstract::Data comparing the patient characteristics, management and outcomes for dabigatran versus warfarin major bleeding in the practice setting are limited. We performed a retrospective single health system study of atrial fibrillation patients with dabigatran or warfarin major bleeding from October 2010 through September 2...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-015-1213-7

    authors: Smythe MA,Forman MJ,Bertran EA,Hoffman JL,Priziola JL,Koerber JM

    更新日期:2015-10-01 00:00:00

  • Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

    abstract::Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02339-6

    authors: Ruberto F,Chistolini A,Curreli M,Frati G,Marullo AGM,Biondi-Zoccai G,Mancone M,Sciarretta S,Miraldi F,Alessandri F,Ceccarelli G,Barone F,Santoro C,Alvaro D,Pugliese F,Pulcinelli FM,Policlinico Umberto I COVID-19 Group.

    更新日期:2021-01-02 00:00:00

  • Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-006-7732-5

    authors: Hull RD,Schellong SM,Tapson VF,Monreal M,Samama MM,Turpie AG,Wildgoose P,Yusen RD

    更新日期:2006-08-01 00:00:00

  • Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.

    abstract::Fibrinogen depletion via catalysis by snake venom enzymes as a therapeutic strategy to prevent or treat thrombotic disorders was utilized for over four decades, with ancrod being the quintessential agent. However, ancrod eventually was found to not be of clinical utility in large scale stroke trial, resulting in the e...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1343-6

    authors: Nielsen VG

    更新日期:2016-08-01 00:00:00

  • Embolic events caused by aortic thrombi: an underestimated entity?

    abstract::Stroke and other thromboembolic events are mainly caused by emboli from heart, aorta and other arteries. In this paper we describe a group of 5 middle-aged patients suffering from emboli caused by large thrombi in the aorta. Since the development of giant thrombi under high flow conditions in the aorta is a pathophysi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-012-0775-x

    authors: Stoevesandt D,Klempt C,Scheubel R,Herr W,Hettwer S,Werdan K,Silber RE,Kraya T,Thews O,Schlitt A

    更新日期:2013-02-01 00:00:00

  • Acquired factor V inhibitors: a systematic review.

    abstract::The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bov...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-010-0529-6

    authors: Franchini M,Lippi G

    更新日期:2011-05-01 00:00:00

  • Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism.

    abstract::Recent gene knockout studies on mice have shown the role of toll-like receptor 9 (TLR9) in resolution of venous thromboembolism (VTE) through sterile inflammation. However, the role of a putative functional TLR9 polymorphism (rs5743836) in risk assessment of VTE recurrence remains unknown. The aim of our study was to ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-017-1491-3

    authors: Ahmad A,Sundquist K,Zöller B,Svensson PJ,Sundquist J,Memon AA

    更新日期:2017-07-01 00:00:00

  • Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

    abstract::There is a significantly increased risk of pregnancy complications in women with anti-phospholipid syndrome (APS). The risk is further heightened in those with previous arterial or venous thromboembolism and so-called 'triple positivity' for anti-phospholipid antibodies (i.e., when lupus anticoagulant, and anti-cardio...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1080-7

    authors: Rose HL,Ho WK

    更新日期:2014-11-01 00:00:00

  • Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group.

    abstract::It has been reported that platelet expression and plasma levels of soluble P-selectin are increased in patients with unstable coronary artery syndromes. However, the origin of soluble P-selectin remains unknown. We sought to determine whether platelet expression of P-selectin correlates with plasma levels in the popul...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1023/a:1018738502654

    authors: Gurbel PA,Kereiakes DJ,Serebruany VL

    更新日期:2000-08-01 00:00:00

  • Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography.

    abstract::A main underlying pathology of coronary artery disease is the deposition of cholesterol in the arteries supplying blood to the heart that leads to stenosis and myocardial infarction. We tested if dyslipidemia is a risk factor for coronary artery disease in the Lebanese population, and studied the role of the total cho...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-014-1069-2

    authors: Platt DE,Ghassibe-Sabbagh M,Youhanna S,Hager J,Cazier JB,Kamatani Y,Salloum AK,Haber M,Romanos J,Doueihy B,Mouzaya F,Kibbani S,Sbeite H,Deeb ME,Chammas E,El Bayeh H,Khazen G,Gauguier D,Zalloua PA,Abchee AB,FGENTCA

    更新日期:2015-01-01 00:00:00

  • Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.

    abstract::Apixaban is effective and safe for preventing stroke, and its usage has increased exponentially in recent years. However, data concerning the therapeutic range of apixaban is limited. This study determined the trough and peak levels of apixaban-specific anti-factor Xa activity (AFXaA) in acute ischemic stroke patients...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1590-1

    authors: Shin H,Cho MC,Kim RB,Kim CH,Choi NC,Kim SK,Koh EH

    更新日期:2018-02-01 00:00:00

  • Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.

    abstract::The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by emulsion solvent evaporation method and optimized using central composite design (CDD). The optimized RXB-PLGA-NPs (F8) with composition, PLGA ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-02022-5

    authors: Anwer MK,Mohammad M,Iqbal M,Ansari MN,Ezzeldin E,Fatima F,Alshahrani SM,Aldawsari MF,Alalaiwe A,Alzahrani AA,Aldayel AM

    更新日期:2020-04-01 00:00:00

  • Direct penetrating and indirect neck trauma as a cause of internal carotid artery thrombosis and secondary ischemic stroke.

    abstract::The following manuscript presents two cases of ischemic stroke secondary to traumatic internal carotid artery thrombosis with concomitant middle cerebral artery thrombosis occurring very rarely in the medico-legal practice. Penetrating neck trauma due to an occupational accident and multiple head and neck trauma secon...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1077-2

    authors: Karnecki K,Jankowski Z,Kaliszan M

    更新日期:2014-10-01 00:00:00

  • Prothrombotic genetic risk factors in patients with very early ST-segment elevation myocardial infarction.

    abstract::The contribution of prothrombotic genetic risk factors in the pathogenesis of premature acute myocardial infarction (MI) is controversial. We examined the prevalence of prothrombotic polymorphisms (G1691A of factor V gene [FV Leiden] and G20210A of prothrombin [FII] gene), deficiencies of natural anticoagulants (prote...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1520-2

    authors: Rallidis LS,Gialeraki A,Tsirebolos G,Tsalavoutas S,Rallidi M,Iliodromitis E

    更新日期:2017-08-01 00:00:00

  • The recognition of acute coronary ischemia in the outpatient setting.

    abstract:BACKGROUND:The missed diagnosis of acute myocardial infarction has been studied in the Emergency Department, but few studies have investigated how often coronary ischemia is correctly identified in the outpatient setting. METHODS:This was a single center retrospective observational study of patients with Health Allian...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0153-2

    authors: Jaffery Z,Hudson MP,Khanal S,Ananthasubramaniam K,Kim H,Greenbaum A,Kugelmass A,Jacobsen G,McCord J

    更新日期:2009-01-01 00:00:00

  • Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.

    abstract::Reticulated platelets (RP) are young, hyperactive platelets that are increased during situations of enhanced platelet turnover such as acute myocardial infarction (AMI). The dynamics of RP levels after AMI is not established. We aimed to characterize the levels of circulating RP over time in patients with AMI. Patient...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1156-4

    authors: Eisen A,Lerman-Shivek H,Perl L,Rechavia E,Leshem-Lev D,Zemer-Wassercug N,Dadush O,Kazum S,Codner P,Kornowski R,Lev EI

    更新日期:2015-07-01 00:00:00

  • Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR.

    abstract::The home prothrombin time/international normalized ratio (PT/INR) self-management could be convenient for patients, enhancing treatment compliance and improving the quality of the oral anticoagulation. However, patient self-management (PSM) of oral anticoagulation may not be feasible for up to half of the patients due...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1335-6

    authors: da Silva Saraiva S,Orsi FA,Santos MP,Machado T,Montalvão S,Costa-Lima C,de Paula EV,Colella MP,Annichino-Bizzacchi J

    更新日期:2016-07-01 00:00:00

  • Aspirin resistance and genetic polymorphisms.

    abstract::Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes. The data are replete relative to the therap...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1022066305399

    authors: Cambria-Kiely JA,Gandhi PJ

    更新日期:2002-08-01 00:00:00

  • Development of a new catheter prototype for laser thrombolysis under guidance of optical coherence tomography (OCT): validation of feasibility and efficacy in a preclinical model.

    abstract::In this feasibility study, a novel catheter prototype for laser thrombolysis under the guidance of optical coherence tomography (OCT) was designed and evaluated in a preclinical model. Human arteries and veins were integrated into a physiological flow model and occluded with thrombi made from the Chandler Loop. There ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1470-0

    authors: Berndt R,Rusch R,Hummitzsch L,Lutz M,Heß K,Huenges K,Panholzer B,Otte C,Haneya A,Lutter G,Schlaefer A,Cremer J,Groß J

    更新日期:2017-04-01 00:00:00

  • Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects.

    abstract::We assessed the contribution of serum homocysteine levels, an independent risk factor for vascular disease, and of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation to the variability of carotid intimal-medial thickness (IMT) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Ninety-five pa...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1008962220476

    authors: Mazza A,Motti C,Nulli A,Pastore A,Andreotti F,Ammaturo V,Bianco P,Santoro E,Federici G,Cortese C

    更新日期:1999-10-01 00:00:00

  • Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

    abstract::Arterial thrombosis is the leading causes of morbidity and mortality worldwide, whereas venous thrombosis is the most common preventable cause of hospital death. In either case, venous and arterial thrombosis should be considered autonomous entities, with only minor overlaps in terms of risk factors, predisposing cond...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-012-0748-0

    authors: Lippi G,Favaloro EJ,Franchini M

    更新日期:2012-10-01 00:00:00

  • Novel sila-amide derivatives of N-acetylcysteine protects platelets from oxidative stress-induced apoptosis.

    abstract::Oxidative stress-induced platelet apoptosis is one among the many causes for the development and progression of many disorders like cardiovascular diseases, arthritis, Alzheimer's disease and many chronic inflammatory responses. Many studies have demonstrated the less optimal effect of N-acetyl cysteine (NAC) in oxida...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1450-4

    authors: Paul M,Thushara RM,Jagadish S,Zakai UI,West R,Kemparaju K,Girish KS

    更新日期:2017-02-01 00:00:00

  • Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study.

    abstract::D-dimer levels are increased in patients with acute pulmonary embolism (PE). However, D-dimer levels are also increased in patients with community-acquired pneumonia (CAP). The aim of this prospective cohort study was to examine the incidence and clinical features of patients preliminarily diagnosed with CAP and with ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1275-6

    authors: Zhang Y,Zhou Q,Zou Y,Song X,Xie S,Tan M,Zhang G,Wang C

    更新日期:2016-05-01 00:00:00

  • Investigation of adverse effects of interactions between herbal drugs and natural blood clotting mechanism.

    abstract::Throughout the world, herbal medicines are consumed by most of the patients without considering their adverse effects. Many herbal medicines/plant extracts have been reported to interact with the natural blood clotting system. In continuation to this effort, thirty medicinal plant extracts were allowed to interact wit...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-015-1269-4

    authors: Adhyapak MS,Kachole MS

    更新日期:2016-05-01 00:00:00

  • The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

    abstract::The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin generation study was conducted within the phase 1 ascending dose s...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-014-1081-6

    authors: Vavalle JP,Rusconi CP,Zelenkofske S,Wargin WA,Ortel TL,Alexander JH,Povsic TJ,Becker RC

    更新日期:2014-10-01 00:00:00

  • Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

    abstract::Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with emerging changes in incidence, diagnosis and treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-015-1313-4

    authors: Khorana AA,Carrier M,Garcia DA,Lee AY

    更新日期:2016-01-01 00:00:00

  • Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry.

    abstract::The optimal antithrombotic therapy for patients undergoing TAVI with concomitant indication for oral anticoagulation remains unclear. In this high-risk population group, there is a paucity of data with regards to the use of DOACs. In the present study we compared long-term clinical outcomes of TAVI patients requiring ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01968-w

    authors: Kalogeras K,Jabbour RJ,Ruparelia N,Watson S,Kabir T,Naganuma T,Vavuranakis M,Nakamura S,Malik IS,Mikhail G,Dalby M,Panoulas V

    更新日期:2020-07-01 00:00:00